Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA.
Bone Marrow Transplant. 2009 Dec;44(12):769-77. doi: 10.1038/bmt.2009.300. Epub 2009 Oct 26.
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2-20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.
异基因造血干细胞移植（allo-SCT）后复发的急性髓系白血病（AML）患者预后极差。尽管二次 allo-SCT 具有治愈作用，但对于大量复发患者而言并非合适的治疗选择（仅有 2-20%的患者接受二次 allo-SCT），目前正在努力增加可能从二次 allo-SCT 中获益的患者数量。此外，对疾病复发中各种生物学过程的了解，鼓励了新型治疗方法的开发，这可能对目前接受支持治疗的复发疾病患者有益。尽管将新型药物联合免疫调节的方法具有理论吸引力，但应在临床试验中进行测试。在这篇综述中，我们讨论了 allo-SCT 后复发 AML 的现有治疗方法。
